Yuki Kogure

Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study

K. Suzuki, Takeharu Yamanaka, Hiroki Hashimoto et al. · Annals of Oncology · 2016 · 97 citations · Full text

Oncology, Metronomic Therapy, Pharmacology +6

Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study

Daiki Tsuji, Mari Yokoi, Kenichi Suzuki et al. · The Pharmacogenomics Journal · 2016 · 25 citations

Antiemetic Efficacy, Cisplatin-based Chemotherapy, Medicine +10

Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.

Hironobu Hashimoto, Takeharu Yamanaka, Yasuhiro Shimada et al. · Journal of Clinical Oncology · 2013 · 17 citations

Emetogenic Chemotherapy, Oncology, Primary Endpoint +11

A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin.

Hironobu Hashimoto, Takako Yanai, Kengo Nagashima et al. · Journal of Clinical Oncology · 2016 · 11 citations

Emetogenic Chemotherapy, Psychotropic Medication, Cancer Management +18

5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

Reiko Matsui, Kenichi Suzuki, Tomomi Takiguchi et al. · BMC Pharmacology and Toxicology · 2020 · 11 citations · Full text